About Us

Universal Cells is a Seattle-based company that is producing engineered stem cell lines that can avoid rejection and be used in allogeneic cell therapy treatments for the people who need them. One Cell, Many Therapies.

U Cells Assets About Intro Hero 01

Our History

Universal Cells was founded to commercialize the gene editing, stem cell engineering, and immune rejection technologies originally developed in David Russell’s laboratory at the University of Washington. Since our founding in 2013, we have rapidly expanded our universal donor cell research and started therapeutic programs.

Astellas - Our Parent Company Image

Astellas - Our Parent Company

Astellas Pharma Inc purchased Universal Cells in February 2018 and we are now a wholly owned subsidiary. Astellas is committed to bringing value to their patients by becoming a leader in Cell Therapy, with a particular emphasis on allogeneic, pluripotent stem cell-derived products. Our relationship with Astellas provides us with unparalleled support for our programs, allowing us to focus entirely on the development of safe and effective cell therapy products.

Visit AstellasArrow Button Link Image
Timeline Image

Leadership

President, Chief Intelligence and Liaison Officer

Noboru Yamaji,
Ph.D

President, Chief Intelligence and Liaison Officer
Founder, Chief Science Officer

David Russell,
MD, Ph.D

Founder, Chief Science Officer
Senior Director of Operational Excellence

Kim Clary,
Ph.D

Senior Director of Operational Excellence
Senior Manager, Human Resources

George Padilla,
SHRM-SCP

Senior Manager, Human Resources

Leads

Associate Director, Natural Killer Cell Engineering

Tamar Boursalian

Associate Director, Natural Killer Cell Engineering
Associate Director, Bioinformatics and Gene Editing

Ryan Davis

Associate Director, Bioinformatics and Gene Editing
Director, Program Management, Late Stage Preclinical Development

Joshua Grimley

Director, Program Management, Late Stage Preclinical Development
Associate Director, Cell Editing and Process Development

Akina Hoshino

Associate Director, Cell Editing and Process Development
Director, Differentiation Research

Vivian Lee

Director, Differentiation Research
Director, Early Drug Discovery Research

Adrian Ozinsky

Director, Early Drug Discovery Research
Director, Core Technologies

Lisa Petek

Director, Core Technologies
Director, CMC Operations

Ross Taylor

Director, CMC Operations